Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study
- PMID: 34296382
- DOI: 10.1007/s11239-021-02512-5
Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study
Abstract
Introduction: Treatment of Venous thromboembolism (VTE) in cancer patients is challenging due to higher risk of VTE recurrence or bleeding under anticoagulants. We assessed the effectiveness of a dedicated "Allo-Thrombosis Cancer" multidisciplinary care program (AlloTC-MCP) that incorporated individualized care, regular follow-ups, telephone counselling, and a patient education program.
Methods and materials: From September 2017 to October 2019, 100 consecutive cancer patients with new VTE onset were enrolled in this observational single-center prospective pilot study and received standard (control group, n = first 50 patients enrolled) or AlloTC-MCP care (n = next 50 patients enrolled) over a 6-month VTE treatment follow-up period. Primary end-point was the percentage of adherence to the International Clinical Practice Guidelines (ITAC-CPGs) at 6 (M6) month follow-up.
Results: Among the 100 patients with different cancer types (22% genitourinary, 19% breast, 16% gastrointestinal, 15% lymphoma, 11% lung and 17% others), 51 patients (61%) had metastatic disease and 31 (31%) received chemotherapy alone. Main baseline cancer and VTE clinical characteristics did not differ between the 2 groups. Adherence rates to ITAC-CPGs was significantly higher in the AlloTC-MCP group (100% (M0), 72% (M3) and 68% (M6)) compared with the control group (84% (M0), 8% (M3) and 16% (M6)). Quality of Life (QoL) was significantly improved in the AlloTC-MCP group 6 months after inclusion.
Conclusion: The "AlloTC-MCP" was associated with improved adherence to ITAC-CPGs and merits further expansion.
Keywords: Anticoagulant; Cancer; Clinical practice guidelines; Multidisciplinary care program; Quality of life; Venous thromboembolism.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41:3–14 - DOI
-
- Timp JF, Braekkan SK, Versteeg HH et al (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122:1712–1723 - DOI
-
- Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464 - DOI
-
- Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9:e1001275 - DOI
-
- Marin-Barrera L, Muñoz-Martin AJ, Rios-Herranz E et al (2019) A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: quality of life in cancer (Qca) study. Cancers (Basel) 12
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous